新型免疫检查点—恶性肿瘤免疫治疗研究进展
DOI: 10.3971/j.issn.1000-8578.2018.18.0545
Keywords: 免疫治疗,免疫检查点,恶性肿瘤,Research Progress of PD-1/PD-L1 Targeted Radionuclide Molecular Probes in Tumor Immunotherapy,Research Progress of Intestinal Microbiota and Immune Checkpoint Inhibitors,A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer,Advances of 125I Radioactive Particle Chain Intracavitary Brachytherapy,Advances in Molecular Mechanisms of Early Bone Metastasis,Progress on Comprehensive Treatment of Nasopharyngeal Cancer,Research Advances on Small Molecule Targets for Tumor Immunotherapy,Infections of Pathogens in Lesions of Cutaneous Carcinoma,Role of SWI/SNF Complex Subunit Abnormality in Tumors and Progress of Related Therapeutic Strategies,Progress of Molecular Imaging in Diagnosis of HER2 Positive Tumors,Challenges of Immune Checkpoint Inhibitors in Treatment of Non-small Cell Lung Cancer,Advances in Metabolic Characteristics of Malignant Tumors and Their Correlation with Inflammatory Mediators,Diagnostic Value of FH Test for Early Screening of Rectal Cancer,Polyinosinic-polycytidylic Acid Mediates PD-1 Expression in T Cells at Early Stage of Activation and Inhibits Melanoma Growth,Research Progress of Formononetin for Anticancer Drug Development
Abstract:
摘要 针对程序性死亡受体1/程序性死亡配体1（PD-1/PD-L1）和细胞毒T淋巴细胞相关抗原4（CTLA-4）位点的免疫治疗药物已应用于临床，并且在临床中的地位和作用逐渐增强，然而这些药物获益人群有限，急需寻找新的治疗靶点并且探索出合适的免疫调节机制来提高恶性肿瘤治疗的疗效。本文从特异性免疫和非特异性免疫两方面对新型免疫检查点的起源、基础研究及相应靶点最新的临床研究结果和正在进行的临床研究进行综述，其中特异性免疫检查点包括T细胞免疫球蛋白黏蛋白3（TIM-3）、淋巴细胞活化基因3（LAG-3）、V区域Ig抑制子（VISTA）等，非特异性免疫检查点包括人类杀伤细胞免疫球蛋白样受体（KIR）、吲哚胺2,3-双加氧酶（IDO）、CD47，期望给临床及基础研究以提示
Full-Text
